B Becton, Dickinson & Co.
| Market Cap | $55.98B |
| P/E Ratio | 25.25 |
| Forward P/E | 11.43 |
| Dividend Yield | 2.72% |
| Beta | 0.35 |
| 52W Range | $126.85 - $184.21 |
| # Hedge Funds | 8 |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
Hedge Fund Ownership
| Investor 8 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Steven Romick First Pacific Advisors | 4.99% | $378.68M | 1,951,246 | Add 108.41% |
| First Eagle Investment Management First Eagle Investment Management | 3.98% | $2.26B | 11,646,000 | Add 16.53% |
| Robert Olstein Olstein Capital Management | 1.84% | $8.00K | 42,500 | Reduce 18.27% |
| Hillman Value Fund Hillman Capital Management | 1.74% | $2.76M | 14,230 | Reduce 15.37% |
| Bill Nygren Harris Associates LP | 0.70% | $551.49M | 2,841,721 | Reduce 8.78% |
| FPA Queens Road Small Cap Value Fund Bragg Financial Advisors | 0.09% | $2.75M | 14,195 | Reduce 16.11% |
| Mairs & Power Growth Fund Mairs & Power Inc | 0.01% | $1.38M | 7,119 | — |
| Jensen Investment Management Jensen Investment Management | 0.01% | $482.00K | 2,486 | — |
Insider Trading
| Insider Name of the company insider who made the trade 14 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Feld MichaelEVP, Chief Revenue Officer | Sale | 75 | $156.83 | $11.76K | 26 Mar 2026 | 26 Mar 2026 |
| Feld MichaelEVP, Chief Revenue Officer | Sale | 75 | $181.84 | $13.64K | 26 Feb 2026 | 27 Feb 2026 |
| SCOTT BERTRAM L | Sale | 953 | $182.61 | $174.03K | 18 Feb 2026 | 18 Feb 2026 |
| Feld MichaelEVP, CRO & Pres. Life Sciences | Sale | 75 | $202.73 | $15.20K | 26 Jan 2026 | 28 Jan 2026 |
| Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Sale | 1,010 | $206.54 | $208.61K | 15 Jan 2026 | 16 Jan 2026 |
| Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Sale | 600 | $209.00 | $125.40K | 15 Jan 2026 | 16 Jan 2026 |
| Feld MichaelEVP, CRO & Pres. Life Sciences | Sale | 74 | $196.08 | $14.51K | 26 Dec 2025 | 29 Dec 2025 |
| Michael FeldEVP, CRO & Pres. Life Sciences | Sale | 74 | $196.08 | $14.51K | 26 Dec 2025 | 29 Dec 2025 |
| Garrison Michael DavidEVP & Pres Med.Essntl&BioPharm | Sale | 629 | $196.03 | $123.30K | 17 Dec 2025 | 17 Dec 2025 |
| Feld MichaelEVP, CRO & Pres. Life Sciences | Sale | 75 | $193.36 | $14.50K | 01 Dec 2025 | 02 Dec 2025 |
| Michael FeldEVP, CRO & Pres. Life Sciences | Sale | 75 | $193.36 | $14.50K | 01 Dec 2025 | 02 Dec 2025 |
| SCOTT BERTRAM L | Sale | 217 | $176.58 | $38.32K | 07 Nov 2025 | 07 Nov 2025 |
| Feld MichaelEVP & President, Life Sciences | Sale | 57 | $186.01 | $10.60K | 27 Oct 2025 | 28 Oct 2025 |
| Michael FeldEVP & President, Life Sciences | Sale | 57 | $186.01 | $10.60K | 27 Oct 2025 | 28 Oct 2025 |
Frequently Asked Questions
What is BDX stock price today?
Becton, Dickinson & Co. (BDX) is currently trading at $154.51. The stock has a 52-week range of $126.85 to $184.21 and a market capitalization of $55.98B.
Is BDX a good stock to buy in 2026?
Becton, Dickinson & Co. has a P/E ratio of 25.2 (forward P/E: 11.4), a dividend yield of 2.72%, and 1-year performance of -9.2%. 8 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling BDX stock?
There have been 14 insider transactions for BDX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has BDX stock performed over the past year?
Becton, Dickinson & Co. (BDX) has returned -9.2% over the past 12 months. The stock traded between $126.85 and $184.21 during this period, and is currently at $154.51.
Which hedge funds own BDX (Becton, Dickinson & Co.)?
8 tracked hedge funds currently hold BDX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is BDX's market cap and valuation?
Becton, Dickinson & Co. (BDX) has a market capitalization of $55.98B. The trailing P/E ratio is 25.2 and forward P/E is 11.4. The stock is classified in the Healthcare sector.
What is BDX's revenue and profitability?
Becton, Dickinson & Co. reported revenue of $21.92B with net income of $1.76B and a profit margin of 0.08%. The stock has a beta of 0.35.
What sector is BDX in and who are its biggest institutional holders?
Becton, Dickinson & Co. (BDX) operates in the Healthcare sector. It is held by 8 tracked hedge funds. See the ownership table above for the complete list.